Answers are grounded in this paper and cite their sources.
Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF). This paper aimed to project the potential impact of dapagliflozin on healthcare costs related to HF subsequent hospitalizations (HFHs) in Portuguese hospitals.
No takes yet. Share an insight, caveat, or question.
Brito et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: